71

Jahon sog'liqni saqlash tashkiloti ma'lumotlariga ko'ra, 2020 yilda yurak ishemik kasalligi (YuIK) rivojlangan mamlakatlar aholisida nogironlik
va o'limning asosiy sabablaridan biri bo'ladi. YuIK ning eng og'ir ko'rinishlaridan biri o'tkir miokard infarkti (MI).
MI patogenezida, ya'ni yurak mushagi ishemik nekrozining rivojlanishida yurak mushagining o'tkir okklyuziyasi natijasida yurak mushagining
ma'lum bir sohasiga koronar arteriya qon ta'minoti to'liq to'xtashi muhim rol o'ynaydi. Koronar arteriyada qon oqimi to'xtaganidan 20-40 minut
o'tgach, kardiomiotsitlarda birinchi degradatsiya o'zgarishlari paydo bo'ladi. Koronar arteriya orqali qon oqimi to'xtatilgandan keyingi dastlabki
soatlarda, miokarddagi mikroskopik nekrotik o'zgarishlardan 10-12 soat o'tgach, miokard nekrozining makroskopik o'choqlari paydo bo'ladi, bu
nekrotik jarayonning kengayishi va chuqurlashishini ko'rsatadi. Bu yurak mushagida koagulyatsion-nekrotik jarayonni va miotsitolizni to'xtatish
uchun koronar arteriyadagi qon oqimini tez va samarali tiklash yo'llarini topish zarurligini belgilaydi. Bugungi kunda ishemiyada miokard
kisloroddan foydalanish samaradorligini oshirishga qaratilgan dorilar guruhi metabolik terapiyadir. Ishemiya va reperfuziya paytida miokard
metabolizmidagi o'zgarishlar dori ta'sirining keng spektrini ochadi. Bizga quyidagi talablarga javob beradigan optimal dori tanlash vazifasi qo‘yildi:
preparat ta’sir mexanizmiga ko‘ra kardiomiotsitga oson va oson kirib boradigan energiya substratiga ega.

  • Read count 71
  • Date of publication 15-03-2023
  • Main LanguageO'zbek
  • Pages59-65
Ўзбек

Jahon sog'liqni saqlash tashkiloti ma'lumotlariga ko'ra, 2020 yilda yurak ishemik kasalligi (YuIK) rivojlangan mamlakatlar aholisida nogironlik
va o'limning asosiy sabablaridan biri bo'ladi. YuIK ning eng og'ir ko'rinishlaridan biri o'tkir miokard infarkti (MI).
MI patogenezida, ya'ni yurak mushagi ishemik nekrozining rivojlanishida yurak mushagining o'tkir okklyuziyasi natijasida yurak mushagining
ma'lum bir sohasiga koronar arteriya qon ta'minoti to'liq to'xtashi muhim rol o'ynaydi. Koronar arteriyada qon oqimi to'xtaganidan 20-40 minut
o'tgach, kardiomiotsitlarda birinchi degradatsiya o'zgarishlari paydo bo'ladi. Koronar arteriya orqali qon oqimi to'xtatilgandan keyingi dastlabki
soatlarda, miokarddagi mikroskopik nekrotik o'zgarishlardan 10-12 soat o'tgach, miokard nekrozining makroskopik o'choqlari paydo bo'ladi, bu
nekrotik jarayonning kengayishi va chuqurlashishini ko'rsatadi. Bu yurak mushagida koagulyatsion-nekrotik jarayonni va miotsitolizni to'xtatish
uchun koronar arteriyadagi qon oqimini tez va samarali tiklash yo'llarini topish zarurligini belgilaydi. Bugungi kunda ishemiyada miokard
kisloroddan foydalanish samaradorligini oshirishga qaratilgan dorilar guruhi metabolik terapiyadir. Ishemiya va reperfuziya paytida miokard
metabolizmidagi o'zgarishlar dori ta'sirining keng spektrini ochadi. Bizga quyidagi talablarga javob beradigan optimal dori tanlash vazifasi qo‘yildi:
preparat ta’sir mexanizmiga ko‘ra kardiomiotsitga oson va oson kirib boradigan energiya substratiga ega.

№ Name of reference
1 Ташкенбаева Э. Н. и др. Изменение сердечного ритма при остром инфаркте миокарда по данным эхокардиографии сердца //Научный журнал. – 2020. – №. 7 (52). – С. 51-54. 2. Муинова К. К. и др. Роль факторов риска в развитии инфаркта миокарда у мужчин молодого возраста в зависимости от семейного анамнеза //Достижения науки и образования. – 2019. – №. 11 (52). – С. 70-74. 3. Alisherovna S. N. et al. A Modern Approach to Risk Stratification in Patients with Heart Failure with Preserved and Reduced Ejection Fraction //Web of Scientist: International Scientific Research Journal. – 2022. – Т. 3. – №. 5. – С. 73-81. 4. Madjidova G. T. et al. Nutritional Support for Patients with Coronavirus Infection //Texas Journal of Medical Science. – 2022. – Т. 13. – С. 22-30. 5. Madjidova G. T. Tactics of treatment of patients with acute coronary syndrome //Texas Journal of Medical Science. – 2022. – Т. 13. – С. 37-42. 6. Madjidova G. T., Sunnatova G. I., Xamidov N. Features of Natriuretic Peptides in the Blood Plasma of Patients with Hypertrophic Cardiomyopathy //Texas Journal of Medical Science. – 2022. – Т. 13. – С. 31-36. 7. Madjidova G. T., Sunnatova G. I., Hamidov N. S. CLINICAL AND HEMODYNAMIC CONDITIONS AND HEART NATRIURETIC PEPTIDES IN THE BLOOD PLASMA OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY //Eurasian Journal of Medical and Natural Sciences. – 2022. – Т. 2. – №. 5. – С. .211-219. 8. Alisherovna S. N. et al. FEATURES OF THE CLINICAL COURSE OF UNSTABLE ANGINA ON THE BACKGROUND OF COPD //Web of Scientist: International Scientific Research Journal. – 2022. – Т. 3. – №. 5. – С. 82-86. 9. Madjidova G. T., Sunnatova G. I., Usarov S. A. ABOUT THE SYSTEM OF TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME //Eurasian Journal of Medical and Natural Sciences. – 2022. – Т. 2. – №. 5. – С. 197-204. 10. Madzhidova G. T., Istamova S. S., Fatullaeva D. S. The effectiveness of the use of biguanides in the combination therapy of hypertension with metabolic syndrome //Medical sciences., S. – 2019. – С. 69-71. 11. Хасанжанова Ф. О. и др. ФАКТОРЫ ВЛИЯЮЩИЕ НА ДИЛАТАЦИЮ ЛЕВОГО ЖЕЛУДОЧКА У БОЛЬНЫХ С НЕСТАБИЛЬНОЙ СТЕНОКАРДИЕЙ НАПРЯЖЕНИЯ //Молодежь и медицинская наука в XXI веке. – 2018. – С. 175-176. 12. Khasanjanova F. O. et al. Evaluation of the effectiveness of thrombolytic therapy in men with acute coronary myocardial infarction in young age //CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2021. – Т. 2. – №. 1. – С. 144-149. 13. Khasanzhanova F. O. et al. EVALUATION OF THE EFFECTIVENESS OF THROMBOLYTIC THERAPY IN MEN WITH ACUTE MYOCARDIAL INFARCTION IN YOUNG AGE //Archive of Conferences. – 2021. – Т. 15. – №. 1. – С. 48-52. 14. Ташкенбаева Э. и др. Особенности развития сердечной недостаточности при дилатационной кардиомиопатии у больных госпитализированных в стационар экстренной медицинской помощи //Журнал проблемы биологии и медицины. – 2018. – №. 3 (102). – С. 79-81
Waiting